NASDAQ$ATXS
Astria Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
ATXS Q4 2023 — $100.0M revenue
We face substantial competition from other pharmaceutical and biotechnology companies, and our operating results may suffer if we fail to compete effectively. Astria Therapeutics Inc reported Q4 2023 results. Net income of $72.9M. Headline numbers extracted from the Form 10-K press release; narrative is light because this row was processed without an LLM call.
- Revenue: $100.0M.
- Net income: $72.9M.
- Filed on Form 10-K (accession 0001410578-24-000127).
Headline financials
Revenue & EPS history
Astria · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports
+1.3%
Avg return
Earnings day
+1.4%
Avg return
5 days after
+0.6%
Avg return
30 days after
52%
22 / 42 earnings
Positive
+19.8%
Q4 2018
Best reaction
-11.6%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +0.2% | +0.5% | +3.3% | |
| Q2 2025 | +3.0% | +1.7% | +11.7% | |
| Q1 2025 | +7.3% | +2.8% | +49.7% | |
| Q4 2024 | +11.2% | +10.8% | -30.2% | |
| Q3 2024 | -9.6% | -17.8% | -14.7% | |
| Q2 2024 | +10.9% | +18.4% | +12.1% | |
| Q1 2024 | +1.7% | -0.9% | -7.6% | |
| Q4 2023 | -7.5% | -4.1% | -19.3% | |
| Q3 2023 | -2.0% | — | — | |
| Q2 2023 | -2.0% | — | — | |
| Q1 2023 | -0.4% | — | — | |
| Q4 2022 | +2.3% | — | — | |
| Q3 2022 | +7.9% | — | — | |
| Q2 2022 | +3.3% | — | — | |
| Q1 2022 | -2.8% | — | — | |
| Q4 2021 | +2.7% | — | — | |
| Q3 2021 | +5.4% | — | — | |
| Q2 2021 | -11.6% | — | — | |
| Q1 2021 | +0.6% | — | — | |
| Q4 2020 | +11.6% | — | — | |
| Q3 2020 | -1.4% | — | — | |
| Q2 2020 | +1.5% | — | — | |
| Q1 2020 | -0.7% | — | — | |
| Q4 2019 | -5.5% | — | — | |
| Q3 2019 | -1.3% | — | — | |
| Q2 2019 | +1.1% | — | — | |
| Q1 2019 | +12.7% | — | — | |
| Q4 2018 | +19.8% | — | — | |
| Q3 2018 | -0.8% | — | — | |
| Q2 2018 | -4.5% | — | — | |
| Q1 2018 | -8.9% | — | — | |
| Q4 2017 | +2.1% | — | — | |
| Q3 2017 | +0.0% | — | — | |
| Q2 2017 | -1.2% | — | — | |
| Q1 2017 | -1.5% | — | — | |
| Q4 2016 | -11.4% | — | — | |
| Q3 2016 | +14.4% | — | — | |
| Q2 2016 | -2.7% | — | — | |
| Q1 2016 | +6.0% | — | — | |
| Q4 2015 | +6.9% | — | — | |
| Q3 2015 | -8.0% | — | — | |
| Q2 2015 | +5.0% | — | — | |
| Q1 2015 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q4 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro